Atara Biotherapeutics, Inc. Price Today
Atara Biotherapeutics, Inc.
ATRA
Healthcare
$77.05M
💰
Market Cap
0
💸
Price to Earnings
$-2.8
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Hold Consensus
Buy |
6 |
Strong Buy |
2 |
Hold |
4 |
Sell |
1 |
Strong Sell |
0 |
ATRA Price Forecast Target
0.8 👉 13.0 +1620%
ATRA EPS Forecast
-2.8 👉 -0.6 +-80%
Financials
Profit Margin
0 %
Revenue Growth
-52.1 %
Dividend
$ 0
Held Percent
6.3% - Insiders
73.7% - Institutions
20.0% - Public
Major Fund Holders
-
💰 EcoR1 Capital, LLC $7.6M
-
💰 Redmile Group, LLC $6.9M
-
💰 Blackrock Inc. $5.4M
-
💰 Vanguard Group Inc $5.1M
-
💰 UBS Group AG $2.8M
Stock Ideas
Jim Simons Portfolio
Jim Simons, the mastermind behind the Medallion Fund, has achieved such extraordinary returns that he has skyrocketed to the ranks of the world's wealthiest individuals. The secret to his success lies in the fund's implementation of high-frequency t…
Israel Englander Portfolio
Israel Englander, a notable figure in the finance industry, began his journey by obtaining his undergraduate degree from NYU before venturing into trading on the American Stock Exchange (AMEX), where he found early success. In 1989, he went on to es…
Warren Buffet Portfolio
Invest like the oracle himself! View the stocks that Warren Buffett holds in the Berkshire Hathaway portfolio.
Elon Musk Portfolio
Enter the visionary world of Elon Musk, a name that needs no introduction in the realms of innovation, entrepreneurship, and technology. With a trailblazing spirit and an unyielding drive, Musk has become a household name, propelling himself to extr…📮FAQ
Some Frequently Asked Questions.
The Atara Biotherapeutics, Inc. industry is Biotechnology
The Atara Biotherapeutics, Inc. sector is Healthcare
The Atara Biotherapeutics, Inc. forecasted predicted Price to Earnings PE ratio is -1.4
The Atara Biotherapeutics, Inc. Price to Earnings PE ratio is 0
The Market Capitalization of Atara Biotherapeutics, Inc. is $77.05M
There are total of 81992611 float shares with 73.7% held by Institutions and 6.3% held by insiders
The MAtara Biotherapeutics, Inc. forecasted Earnings per Share EPS is $-0.6
The Atara Biotherapeutics, Inc. Earnings per Share EPS is -2.8
The Atara Biotherapeutics, Inc. company has $0 gross profits with 0 profit margins
The Atara Biotherapeutics, Inc. Earnings Growth is 0% with 0% quarterly earnings growth
The Atara Biotherapeutics, Inc. Revenue is $4542000 with -0.521 revenue growth
The price target for Atara Biotherapeutics, Inc. stock is $13.0 for the high target and $0.5 for the low target
The consensus analyst recommendations for Atara Biotherapeutics, Inc. is Hold, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Atara Biotherapeutics, Inc. is Hold, with the following breakdown:
- Buy: 6
- Strong Buy: 2
- Hold: 4
- Sell: 1
- Strong Sell: 0
The Beta of Atara Biotherapeutics, Inc. is 0
The dividend of Atara Biotherapeutics, Inc. is $0
The dividend yield of Atara Biotherapeutics, Inc. is 0%
The biggest institutional and mutual fund holders of Atara Biotherapeutics, Inc. stock are
- EcoR1 Capital, LLC
- Redmile Group, LLC
- Blackrock Inc.
- Vanguard Group Inc
The Atara Biotherapeutics, Inc. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0